Aspire-Lakewood Holdings, Inc. (ASBP) company profile
Close on Nov 17, 2026Market cap $11.64MP/E –Yield –
About Aspire-Lakewood
Pharmaceutical Preparations, SIC 2834
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical firm that develops and commercializes novel sublingual delivery technologies designed for known pharmaceuticals and nutraceuticals. Its proprietary delivery mechanism provides rapid sublingual absorption directly into the bloodstream in soluble powder or granule form, bypassing the gastrointestinal tract to minimize side effects and enhance therapeutic efficacy. The company primarily targets emergency care and acute conditions, initially developing a high-dose sublingual aspirin candidate intended for heart attack and stroke prevention, acute pain relief, and emergency intervention. Its planned customer base includes hospitals, specialty care settings, and medical practitioners treating cardiovascular and pain management patients.
The business operates primarily in the United States, planning future overseas distribution through partner arrangements. The company utilizes third-party contract development and manufacturing organizations located in New Jersey and Pennsylvania for production. Aspire Biopharma Holdings maintains its principal corporate headquarters in Estero, Florida.
Summary of the business section of Aspire-Lakewood's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aspire-Lakewood Holdings, Inc.
- Founded
- 2021
- Headquarters
- Estero, FL
- Address
- 23150 Fashion Drive, Suite 232 33928
- Phone
- (561) 704-8527
- Website
- aspirebiolabs.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- Bush & Associates CPA LLC, Las Vegas, Nevada
Stock & identifiers
- Ticker
- ASBP
- Other tickers
- ASBPW
- Former tickers
- PWUP until Feb 20, 2025
- Exchange
- Nasdaq
- IPO date
- Feb 22, 2022
- Shares outstanding
- 1M, Aug 7, 2026
- Public float
- $17.40M, Dec 31, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-40 reverse, Jan 16, 2026
- SEC CIK
- 1847345
- CUSIP
- 738920305
- ISIN
- US7389203057
- FIGI
- BBG015STV133
- Share class FIGI
- BBG015STV142
- LEI
- 529900UC0AFER5IEH285
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Donald G. Fell | Director | 20,000 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Feb 22, 2022
- Offer price
- $10.00
- Securities offered
- 25,000,000
- Gross proceeds
- $250.00M
- Exchange
- Nasdaq
- First trading day
- Apr 11, 2022
- Lock-up ends (est.)
- Oct 8, 2022
“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-half of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
See a number that looks wrong?